Greenland Mines (NASDAQ: GRML) has announced a series of corporate milestones as it sharpens its focus on rare earths and critical minerals, including plans to spin off its biotechnology division in the fourth quarter of 2026. The company also confirmed that Nasdaq has formally approved its application related to the March 2026 transaction, resolving prior deficiencies and ensuring full compliance with listing requirements. Additionally, Greenland Mines completed the acquisition of the Sarfartoq project on September 1, following approval by the Government of Greenland.
The Sarfartoq project, located in southwest Greenland, is a significant neodymium-praseodymium (NdPr) rare earths deposit. An independent S-K 1300 Initial Assessment for the ST1 deposit estimated a high-case pre-tax net present value of approximately $2.05 billion and a pre-tax internal rate of return of 118.6%. This highlights the project's economic viability and strategic importance. Greenland Mines stated that planned annual NdPr oxide production from ST1 would equal approximately 34% of current NdPr oxide refining outside China, based on 2025 consumption levels, during each of the project's nine scheduled operating years. This positions Greenland Mines as a potential major supplier in the non-Chinese rare earth market, which is crucial for diversifying the global supply chain.
As part of its strategic realignment, Greenland Mines is reshaping its board of directors. Riad El-Dada and Dr. Shalom Hirschman are stepping down, and capital markets veteran Jason Hawkins is joining the board. This change brings fresh expertise as the company advances the Sarfartoq project and its Skaergaard palladium-gold-platinum project in southeast Greenland. The Skaergaard project adds a precious metals component to the company's portfolio, further diversifying its asset base.
The spin-off of the biotech division, which includes the development of Klotho's KLTO-202 for ALS, is set for Q4 2026. This move will allow Greenland Mines to concentrate solely on its mining and critical minerals operations, potentially increasing operational efficiency and investor focus. The biotech division, while promising, operates in a different sector, and separating it may unlock value for shareholders.
The company's strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals, and selected midstream processing opportunities. This aligns with its broader North Atlantic Critical Metals Corridor vision, linking Greenland resources with allied downstream jurisdictions and industrial infrastructure. This vision could enhance supply chain security for Western nations, reducing reliance on Chinese rare earth processing.
For the mining industry, this development underscores the growing importance of Greenland as a source of critical minerals. The Sarfartoq project's high NdPr output could help meet the rising demand for permanent magnets used in electric vehicles and wind turbines, supporting the global energy transition. Moreover, the Skaergaard project adds to Greenland's mineral wealth, potentially attracting further investment in the region.
The full press release with additional details is available at https://ibn.fm/QN1U9. For the latest news and updates on Greenland Mines, visit their newsroom at https://ibn.fm/GRML.
Forward-looking statements in this announcement involve risks and uncertainties, as detailed in the company's filings with the SEC. Investors are cautioned not to place undue reliance on these statements, which are based on information available as of the date of the release.
